Dr Graham Kelly: Well, owning a drug that potentially could mean...

Dr Graham Kelly: Well, owning a drug that potentially could mean the difference between immuno-oncology drugs having annual sales of US $20 billion a year at the current time, to something predicted to be in excess of a $100 billion, that's something that we expect the industry and the market to value appropriately in due course. And having started the process of protecting our IP, that means that we are now able to start conversations with large pharma companies that have these immuno-oncology drugs. This is an extraordinarily competitive field, so we are confident that, in due course, we can forge a partnership with one of the key players".

Final specifications for Noxopharm's patent application immuno-oncology therapy were lodged on 16 July 2020. The way is now clear to do a deal with the owner of an under-performing i-o drug that targets PD1, such as Merck (Keytruda) or BMS (Opdivo).

Go get 'em, Graham!